Related Experiment Video
Updated: Apr 19, 2026

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS
Published on: September 7, 2016
Cholesterol-mediated surfactant dysfunction is mitigated by surfactant protein A
Joshua Qua Hiansen1, Eleonora Keating2, Alex Aspros1
1Department of Physiology & Pharmacology, The University of Western Ontario, London, Ontario, Canada.
High cholesterol in pulmonary surfactant impairs lung function, especially in ventilated patients. Surfactant protein A (SP-A) can reverse this cholesterol-induced inhibition, improving lung physiology.
Area of Science:
- Pulmonary medicine
- Biophysics
- Biochemistry
Background:
- Pulmonary surfactant's surface tension reduction is vital for lung function.
- Impaired surfactant function is linked to various lung diseases.
- Elevated surfactant cholesterol levels are implicated in surfactant dysfunction.
Purpose of the Study:
- To investigate if high cholesterol inhibits human surfactant biophysical function.
- To determine if surfactant protein A (SP-A) can reverse cholesterol-induced inhibition.
- To explore the role of cholesterol in surfactant dysfunction in mechanically ventilated patients.
Main Methods:
- Analysis of surfactant from mechanically ventilated trauma patients.
- In vitro experiments using captive bubble surfactometry (CBS) with cholesterol sequestration.
- Reconstitution of surfactant with varying cholesterol concentrations, with and without SP-A.
- In vivo testing in surfactant-depleted rats.
Main Results:
- Cholesterol sequestration in vitro improved surfactant surface activity.
- Surfactant function was inhibited at cholesterol levels of 10% (w/w phospholipid).
- Surfactant protein A (SP-A) mitigated cholesterol-induced inhibition in vitro and in vivo.
Conclusions:
- Cholesterol-induced surfactant inhibition contributes to lung impairment in mechanically ventilated patients.
- SP-A plays a crucial role in maintaining surfactant function despite high cholesterol levels.
- Targeting cholesterol or enhancing SP-A may be therapeutic strategies for lung diseases.
More Related Videos
06:22Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
Published on: April 7, 2021
10:30Author Spotlight: Developing a Microfluidic Lung-on-Chip Model for In-Depth Study of Human Immune Response and Infection Mechanisms
Published on: May 31, 2024
Related Concept Videos
Breathing
Cystic Fibrosis: Management
Sinus disease and chronic...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Obstructive Pulmonary Disease II: Emphysema
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation